GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1352 BetaxololSummary: βadrenergic receptor blocker -
B7312 PSB 603Summary: Adenosine A2B receptor antagonist -
C4753 AVE-1625Summary: highly potent, selective antagonist for CB1 receptor -
B1351 Xylazine HClSummary: α2 Adrenoceptor agonist -
B2234 Clomipramine HClSummary: SERT/NET dopamine transporter (DAT) blocker -
B7283 2-ChloroadenosineSummary: adenosine receptor agonist -
C4711 AM6545Summary: CB1 selective neutral antagonist -
B1350 Timolol MaleateSummary: Non-selective, beta-adrenergic receptor antagonist -
B2233 Azasetron HClSummary: 5-HT3 receptor antagonist -
B7173 MRS 1754Summary: adenosine A2B receptor antagonist
